Young Blood Plasma Multiple Sclerosis Study One-Month Results Show Dramatic Improvements in Critical Disease-Conditions Such as Fatigue, Mobility, Concentration, and Urinary Control
HOUSTON, Feb. 19, 2019 /PRNewswire/ -- The Neurology Center, a medical group practice of top doctors devoted to excellence in care, located in Houston, Texas, working in conjunction with two leading neurology and anti-aging specialists from Houston, has made available one-month results of their randomized controlled study of intravenously administering NuPlasma® young blood plasma into the first thirteen of twenty Multiple sclerosis (MS) disease patients.
MS is one of the world's most common neurologic disorders, and in many countries it is the leading cause of nontraumatic neurologic disability. Nearly one million people are living with MS in the United States. MS is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. FDA-approved medications currently in use have been shown to "modify" the course of MS by reducing the number of relapses and delaying progression of disability to some degree, but do not constitute a cure.
The Neurology Center, in an unprecedented, randomized double-blind, placebo-controlled study, designed to evaluate the efficacy of 25 ml/kg intravenous NuPlasma® young Fresh Frozen Plasma (yFFP®) administered in two doses over three days, realized dramatic improvements in critical disease-conditions such as fatigue, mobility, concentration, and urinary control. These positive initial results reflects the Parkinson's disease (PD) patient results, in which PD patients infused with NuPlasma experienced significant improvements in pain, facial expression, speech, handwriting, tremors, rigidity and falling: https://www.prnewswire.com/news-releases/young-blood-plasma-parkinsons-disease-study-one-month-results-to-be-introduced-at-the-texas-neurological-society-winter-conference-in-austin-on-february-1st-300787105.html.
Importantly, the MS and PD improvements have been obtained "on top of" each patient's current standardized max therapy. Full and continuing study disease assessment, blood laboratory data, references, analyses and the protocol for both MS and PD patients is accessible online at: www.youngplasmastudy.com.
About NuPlasma:
NuPlasma is an accredited Blood Bank operating under FDA, AABB and CLIA's Good Manufacturing Practice regulations. Located in San Marcos, Texas, NuPlasma is the world's first blood bank to collect young plasma exclusively from volunteer donors between 18 to 25 years old. NuPlasma is dedicated to Making Lives Better® by providing physicians with exceptional quality, selection and service.
*The use of Blood and Blood Products such as Plasma in the United States is restricted only to the issuance of a prescription by a licensed physician.
Media Contact:
Patricia Wiginton
Young Plasma Study
512 749-4804
209621@email4pr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/young-blood-plasma-multiple-sclerosis-study-one-month-results-show-dramatic-improvements-in-critical-disease-conditions-such-as-fatigue-mobility-concentration-and-urinary-control-300797849.html
SOURCE The Neurology Center